Literature DB >> 16231052

Gutless adenovirus: last-generation adenovirus for gene therapy.

R Alba1, A Bosch, M Chillon.   

Abstract

Last-generation adenovirus vectors, also called helper-dependent or gutless adenovirus, are very attractive for gene therapy because the associated in vivo immune response is highly reduced compared to first- and second-generation adenovirus vectors, while maintaining high transduction efficiency and tropism. Nowadays, gutless adenovirus is administered in different organs, such as the liver, muscle or the central nervous system achieving high-level and long-term transgene expression in rodents and primates. However, as devoid of all viral coding regions, gutless vectors require viral proteins supplied in trans by a helper virus. To remove contamination by a helper virus from the final preparation, different systems based on the excision of the helper-packaging signal have been generated. Among them, Cre-loxP system is mostly used, although contamination levels still are 0.1-1% too high to be used in clinical trials. Recently developed strategies to avoid/reduce helper contamination were reviewed.

Mesh:

Year:  2005        PMID: 16231052     DOI: 10.1038/sj.gt.3302612

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  80 in total

Review 1.  Gene therapy for the treatment of chronic peripheral nervous system pain.

Authors:  William F Goins; Justus B Cohen; Joseph C Glorioso
Journal:  Neurobiol Dis       Date:  2012-06-02       Impact factor: 5.996

Review 2.  The transgenic animal platform for biopharmaceutical production.

Authors:  L R Bertolini; H Meade; C R Lazzarotto; L T Martins; K C Tavares; M Bertolini; J D Murray
Journal:  Transgenic Res       Date:  2016-01-28       Impact factor: 2.788

Review 3.  Recombinant adenovirus as a methodology for exploration of physiologic functions of growth factor pathways.

Authors:  Kevin Wei; Frank Kuhnert; Calvin J Kuo
Journal:  J Mol Med (Berl)       Date:  2007-09-22       Impact factor: 4.599

Review 4.  The companions: regulatory T cells and gene therapy.

Authors:  Saman Eghtesad; Penelope A Morel; Paula R Clemens
Journal:  Immunology       Date:  2009-05       Impact factor: 7.397

Review 5.  Targeted gene therapy for the treatment of heart failure.

Authors:  Kleopatra Rapti; Antoine H Chaanine; Roger J Hajjar
Journal:  Can J Cardiol       Date:  2011 May-Jun       Impact factor: 5.223

Review 6.  The use of β-cell transcription factors in engineering artificial β cells from non-pancreatic tissue.

Authors:  D Gerace; R Martiniello-Wilks; B A O'Brien; A M Simpson
Journal:  Gene Ther       Date:  2014-10-23       Impact factor: 5.250

7.  Implications of the innate immune response to adenovirus and adenoviral vectors.

Authors:  Seth M Gregory; Shoab A Nazir; Jordan P Metcalf
Journal:  Future Virol       Date:  2011-03       Impact factor: 1.831

8.  First step in characterization of cis-acting sequences involved in fowl adenovirus 1 (CELO) packaging and its effect on the development of a helper-dependent vector strategy.

Authors:  Claire Barra; Patrick Langlois
Journal:  Virus Genes       Date:  2008-09-30       Impact factor: 2.332

Review 9.  Harnessing the RNA interference pathway to advance treatment and prevention of hepatocellular carcinoma.

Authors:  Patrick Arbuthnot; Liam-Jed Thompson
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

10.  Using viral vectors as gene transfer tools (Cell Biology and Toxicology Special Issue: ETCS-UK 1 day meeting on genetic manipulation of cells).

Authors:  Joanna L Howarth; Youn Bok Lee; James B Uney
Journal:  Cell Biol Toxicol       Date:  2009-10-15       Impact factor: 6.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.